1. Home
  2. EIC vs GNFT Comparison

EIC vs GNFT Comparison

Compare EIC & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • GNFT
  • Stock Information
  • Founded
  • EIC N/A
  • GNFT 1999
  • Country
  • EIC United States
  • GNFT France
  • Employees
  • EIC N/A
  • GNFT N/A
  • Industry
  • EIC Finance/Investors Services
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EIC Finance
  • GNFT Health Care
  • Exchange
  • EIC Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • EIC 349.4M
  • GNFT 214.5M
  • IPO Year
  • EIC 2019
  • GNFT 2019
  • Fundamental
  • Price
  • EIC $13.80
  • GNFT N/A
  • Analyst Decision
  • EIC Strong Buy
  • GNFT Strong Buy
  • Analyst Count
  • EIC 1
  • GNFT 1
  • Target Price
  • EIC $17.50
  • GNFT $13.00
  • AVG Volume (30 Days)
  • EIC 250.2K
  • GNFT 4.2K
  • Earning Date
  • EIC 08-05-2025
  • GNFT 04-24-2025
  • Dividend Yield
  • EIC 17.39%
  • GNFT N/A
  • EPS Growth
  • EIC N/A
  • GNFT N/A
  • EPS
  • EIC 0.55
  • GNFT 0.03
  • Revenue
  • EIC $51,224,692.00
  • GNFT $73,187,701.00
  • Revenue This Year
  • EIC $42.67
  • GNFT $15.98
  • Revenue Next Year
  • EIC $29.16
  • GNFT N/A
  • P/E Ratio
  • EIC $25.02
  • GNFT $125.14
  • Revenue Growth
  • EIC 68.61
  • GNFT 105.01
  • 52 Week Low
  • EIC $12.63
  • GNFT $2.55
  • 52 Week High
  • EIC $16.71
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • EIC 56.71
  • GNFT 46.56
  • Support Level
  • EIC $13.62
  • GNFT $3.61
  • Resistance Level
  • EIC $13.83
  • GNFT $3.95
  • Average True Range (ATR)
  • EIC 0.18
  • GNFT 0.14
  • MACD
  • EIC 0.09
  • GNFT -0.01
  • Stochastic Oscillator
  • EIC 89.17
  • GNFT 50.64

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: